Nanjing Leads Biolabs Reshapes Board With Non-Executive Director Change

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) just unveiled an announcement.

Nanjing Leads Biolabs announced that non-executive director Dr. Ni Jia will resign from the board with effect from March 27, 2026, as he steps back from current business roles to focus on future commitments, with the company emphasizing there is no disagreement behind his departure. The board plans to appoint biopharmaceutical industry veteran Dr. Wu Fenglan as a new non-executive director, subject to shareholder approval at the annual general meeting, adding extensive R&D, fundraising and healthcare investment experience that could strengthen the company’s governance and strategic positioning.

Following a recommendation from the nomination committee, Dr. Wu’s proposed appointment underscores the company’s intent to deepen its expertise in innovative drugs and healthcare investments at the board level. Her background at multinational pharma, Hong Kong-listed biotech, private equity and as a biotech founder is expected to provide additional insight into capital markets and drug development, supporting Nanjing Leads Biolabs’ long-term growth and industry competitiveness.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a biopharmaceutical company based in China and listed in Hong Kong, focused on developing innovative drugs and related healthcare solutions. The group operates through research, development and commercialization activities aimed at advancing treatments in the broader biotechnology and pharmaceutical markets.

Average Trading Volume: 620,606

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$13.39B

See more data about 9887 stock on TipRanks’ Stock Analysis page.